[go: up one dir, main page]

WO2018021471A1 - Composition alimentaire pour améliorer la fonction cérébrale - Google Patents

Composition alimentaire pour améliorer la fonction cérébrale Download PDF

Info

Publication number
WO2018021471A1
WO2018021471A1 PCT/JP2017/027233 JP2017027233W WO2018021471A1 WO 2018021471 A1 WO2018021471 A1 WO 2018021471A1 JP 2017027233 W JP2017027233 W JP 2017027233W WO 2018021471 A1 WO2018021471 A1 WO 2018021471A1
Authority
WO
WIPO (PCT)
Prior art keywords
protein hydrolyzate
walnut protein
peptide
brain function
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2017/027233
Other languages
English (en)
Japanese (ja)
Inventor
嵩志 市瀬
孝太郎 西
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fuji Oil Co Ltd (fka Fuji Oil Holdings Inc)
Original Assignee
Fuji Oil Holdings Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fuji Oil Holdings Inc filed Critical Fuji Oil Holdings Inc
Priority to JP2018506349A priority Critical patent/JPWO2018021471A1/ja
Priority to CN201780046792.8A priority patent/CN109561728A/zh
Publication of WO2018021471A1 publication Critical patent/WO2018021471A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/185—Vegetable proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/52—Juglandaceae (Walnut family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the present invention relates to a food composition for improving brain function.
  • Walnuts are widely cultivated in various countries around the world, mainly in Europe and America, Asia, and in Japan, Nagano and Yamagata prefectures. Among them, it is one of the foods that have been loved as a health food since ancient times in China, and has been used in Chinese medicine as a nourishing medicine. In recent years, the consumption of walnuts in China has increased so much that it cannot be covered by domestic production, and the amount of imports has also increased.
  • Non-patent Document 1 ⁇ -3 fatty acids such as ⁇ -linolenic acid and docosahexaenoic acid, melatonin, vitamin E and flavonoids.
  • ⁇ -3 fatty acids such as ⁇ -linolenic acid and docosahexaenoic acid, melatonin, vitamin E and flavonoids.
  • Non-Patent Document 1 ⁇ -3 fats and oils contained in walnuts are listed. It has been suggested that there is an effect of improving brain function.
  • walnuts contain flavonoids that are generally known to have a brain function improving effect (Non-patent Document 1).
  • Non-Patent Document 1 ⁇ -3 fats and oils are generally subject to deterioration due to oxidation, and even when only ⁇ -3 fats and oils are extracted from walnuts, deterioration due to storage occurs, and long-term storage at room temperature is required. There is a problem that it is not suitable for food applications. Further, since the amount of flavonoids contained in walnuts is very small, it is very expensive to extract only flavonoids contained in walnuts, and there is a problem that they are generally not suitable for consumption as food.
  • An object of the present invention is to provide a food material having a function of improving brain function, which has high storage stability and can be taken at low cost.
  • the present inventors diligently investigated the above problems.
  • the inventors have examined whether walnut protein has a brain function improving effect, and it has been found that a walnut protein hydrolyzate has a function of improving brain function. Further examination revealed that the content of the peptide having a molecular weight of less than 500 in the walnut protein hydrolyzate was 55% by weight or more based on the total amount of the peptide and free amino acid, and tyrosine and / or phenylalanine was used as a constituent amino acid.
  • the present inventors have found that a walnut protein hydrolyzate having a dipeptide and / or a tripeptide having an excellent brain function improving effect has been completed.
  • the present invention Dipeptide having a walnut protein hydrolyzate containing a peptide having a molecular weight of less than 500 of 55% by weight or more based on the total amount of peptide and free amino acid, and having tyrosine and / or phenylalanine as constituent amino acids And / or a food composition for preventing cranial nerve disease or improving brain function, comprising a walnut protein hydrolyzate having a tripeptide as an active ingredient, (2) Prevention of cranial nerve disease or improvement of brain function according to (1), wherein the content of the peptide having a molecular weight of less than 500 in the walnut protein hydrolyzate is 60% by weight or more based on the total amount of the peptide and free amino acids.
  • Food composition for (3) The ratio of tyrosine to the total amount of amino acids in the walnut protein hydrolyzate is 3% by weight or more, and the ratio of phenylalanine is 4.5% by weight or more.
  • Food composition for preventing or improving brain function (4) The food composition for preventing or improving brain function according to (1) or (2), wherein the prevention or improvement of brain function of cranial nerve disease is by promoting the release of catecholamine in the brain into the brain.
  • An agent for improving brain function comprising, as an active ingredient, a walnut protein hydrolyzate having a tripeptide / (6)
  • Use of walnut protein hydrolyzate to prevent cranial nerve disease or improve brain function (7)
  • the content of the peptide having a molecular weight of less than 500 in the walnut protein hydrolyzate is 55% by weight or more based on the total amount of the peptide and free amino acid, and as a constituent amino acid
  • Walnut protein hydrolyzate for use in (13)
  • the walnut for use in the prevention or improvement of brain function according to (11) or (12), wherein the prevention or improvement of brain function is caused by promotion of catecholamine release in the cerebral cortex.
  • Protein hydrolyzate It is.
  • the present invention (1) Dipeptide having a walnut protein hydrolyzate containing a peptide having a molecular weight of less than 500 of 55% by weight or more based on the total amount of peptide and free amino acid, and having tyrosine and / or phenylalanine as constituent amino acids And / or a food composition for preventing cranial nerve disease or improving brain function, comprising a walnut protein hydrolyzate having a tripeptide as an active ingredient, (2) The prevention or brain function of cranial nerve disease according to (1), wherein the ratio of tyrosine to the total amount of amino acids in the walnut protein hydrolyzate is 3% by weight or more and the ratio of phenylalanine is 4.5% by weight or more.
  • Food composition for improvement (3) Food composition for preventing or improving brain function according to (1) or (2), wherein the prevention or improvement of brain function is due to the promotion of catecholamine release in the cerebral cortex.
  • An agent for improving brain function comprising, as an active ingredient, a walnut protein hydrolyzate having a tripeptide / It is.
  • ⁇ Ingestion of walnut protein hydrolyzate of the present invention can be used to improve brain function
  • the walnut protein composition used in the present invention can be prepared from a walnut as a raw material, or can be prepared from a defatted walnut cake obtained by removing fats and oils from the walnut, but can be prepared from a defatted walnut cake. preferable.
  • the crude protein content of the walnut protein composition is preferably high, preferably 60% by weight or more based on the dry weight of the walnut protein composition, 70% by weight More preferably, it is more preferably 80% by weight or more.
  • the walnut protein hydrolyzate used in the present invention is a peptide mixture obtained by subjecting the walnut protein composition to protease treatment.
  • the walnut protein hydrolyzate preferably has a higher degree of degradation, and it is particularly important that the proportion of dipeptides and / or tripeptides in the total amount of peptides and free amino acids in the hydrolyzate is high. Specifically, the proportion of dipeptide and / or tripeptide in the total amount of peptide and free amino acid needs to be 55% by weight or more, and preferably 60% by weight or more.
  • a dipeptide and / or a tripeptide is defined as a fraction obtained by removing free amino acids from a fraction having a molecular weight of 500 or less. Therefore, the proportion of dipeptides and / or tripeptides in the total amount of peptides and free amino acids is determined by amino acid analysis after measuring the proportion of peptide fractions with a molecular weight of 500 or less in the hydrolyzate by gel filtration chromatography for peptides. It can be calculated by subtracting the free amino acid content in the measured hydrolyzate.
  • the content of free amino acids in the hydrolyzate is preferably 10% by weight or less, and more preferably 5% by weight or less.
  • the proportion of the fraction having a molecular weight of 500 or more in the total amount of peptide and free amino acid in the hydrolyzate is preferably 40% by weight or less, and 35% by weight. It is more preferable that it is% or less.
  • the walnut protein hydrolyzate of the present invention contains dipeptides and / or tripeptides containing tyrosine and / or phenylalanine. That is, the present invention essentially consists of allowing the dipeptide and / or tripeptide containing tyrosine and / or phenylalanine to act as an active ingredient that improves brain function.
  • the dipeptide and / or tripeptide containing tyrosine and / or phenylalanine contains one or two tyrosine residues or phenylalanine residues.
  • Tripeptides contain 1 to 3 residues of tyrosine or phenylalanine.
  • peptides specifically, as dipeptides, Lys-Tyr, Tyr-Lys, Gly-Tyr, Tyr-Gly, Asn-Tyr, Tyr-Gln, Ala-Tyr, Arg-Tyr, Tyr-Arg , Met-Tyr, Tyr-Met, Pro-Tyr, Tyr-Pro, Tyr-His, His-Tyr, Thr-Tyr, Ile-Tyr, Tyr-Leu, Gln-Tyr, Tyr-Ser, Val-Tyr, Tyr -Ile, Ser-Tyr, Tyr-Asn, Phe-Tyr, Glu-Tyr, Tyr-Glu, Tyr-Thr, Leu-Tyr, Tyr-Val, or Tyr-Ala. Arg-Tyr, Tyr-Asn, Phe-Tyr or Tyr-Phe is preferable. More preferably, it is Phe-Tyr.
  • the ratio of tyrosine and / or phenylalanine in the walnut protein hydrolyzate to the total amino acid amount is preferably 3% by weight or more for tyrosine, and preferably 4.5% by weight or more for phenylalanine.
  • protease treatment is performed using a slurry or an aqueous solution of the walnut protein composition as a substrate.
  • the protease used here is of animal origin, plant origin or microbial origin, and is classified into “metal protease”, “acidic protease”, “thiol protease”, “serine protease” in the classification of protease, preferably “metal” It can be appropriately selected from proteases classified as “protease”, “thiol protease”, and “serine protease”.
  • a degradation method in which enzymes belonging to two or more, or three or more different classifications are allowed to act sequentially or simultaneously can increase the proportion of relatively low molecular weight peptides such as dipeptides and tripeptides.
  • protease is a classification method based on the type of amino acid at the active center, which is usually performed in the field of enzyme science.
  • Metal Protease includes Bacillus Neutral Protease, Streptomyces Neutral Protease, Aspergillus Neutral Protease, “Samoase”, etc.
  • Protease includes bromelain, papain and the like
  • serine protease includes trypsin, chymotrypsin, subtilisin, Streptomyces alkaline protease, “Alcalase”, “Biolase” and the like.
  • the classification of other enzymes can also be confirmed by the working pH and reactivity with inhibitors.
  • an enzyme degradation product can be produced more efficiently by using together enzymes from different origins (origin organisms). Even in the same classification, if the origin is different, the site of action on the protein that is the substrate is also different, and as a result, the proportion of dipeptides and tripeptides can be increased. These proteases preferably have low exo activity.
  • the reaction pH and reaction temperature for protease treatment may be set in accordance with the characteristics of the protease to be used. Usually, the reaction pH is carried out near the optimum pH, and the reaction temperature may be carried out around the optimum temperature. In general, the reaction can be carried out at a reaction temperature of 20 to 80 ° C., preferably 40 to 60 ° C. After the reaction, the enzyme is heated at a temperature sufficient to inactivate the enzyme (about 60 to 170 ° C.) to inactivate the remaining enzyme activity.
  • the reaction solution after the protease treatment can be used as it is or after being concentrated, but is usually sterilized, spray-dried, freeze-dried, etc., and can be used in a dry powder state.
  • Sterilization is preferably heat sterilization, and the heating temperature is preferably 110 to 170 ° C, more preferably 130 to 170 ° C.
  • the heating time is preferably 3 to 20 seconds.
  • the reaction solution can be adjusted to an arbitrary pH, and precipitates and suspensions generated during pH adjustment can be removed by centrifugation, filtration, or the like. Furthermore, it can also refine
  • Cranial nerve diseases include higher brain dysfunction such as memory disorder, attention disorder, executive dysfunction, social behavior disorder, and symptoms pathologically related to these disorders such as cerebral infarction, head injury, brain Examples include vascular dementia, Alzheimer type dementia, Parkinson's disease, schizophrenia, depression, and anxiety. Specific examples of the brain function improvement effect include memory improvement, learning ability improvement, attention improvement, stress tolerance, antidepressant action, anxiolytic action, concentration improvement, and sleep quality improvement.
  • the concentration of catecholamine in the brain in the cerebral cortex is increased by using the walnut protein hydrolyzate containing a dipeptide and / or a tripeptide containing tyrosine and / or phenylalanine. Increases the concentrations of noradrenaline and its metabolites 3-methoxy-4-hydroxyphenylglycol and dopamine in the cerebral cortex.
  • An increase in the concentration of catecholamine in the brain can be expected to prevent cranial nerve disease or improve brain function.
  • the walnut protein hydrolyzate of the present invention can be used by appropriately mixing with other raw materials as necessary in the form of pharmaceuticals or added to food or feed.
  • a pharmaceutical form it can be used in various forms such as liquid, powder, tablet, capsule and the like.
  • solid foods such as biscuits, cakes, bread, food bars, meat products, etc., dissolved in water as a beverage, or yogurt, There is no problem in mixing with fluid and semi-solid foods such as pudding.
  • sugars, vitamins, minerals, etc. can be mixed and used as supplements.
  • When provided as a form mixed with feed it can be used by mixing with known feed without being limited to land and fishery.
  • bioplase oil: Bacillus sp., Serine protease, manufactured by Nagase Chemtech
  • second protease was added at 1% by weight per protein, and the pH was adjusted to 58. It was allowed to act at 60 ° C. for 60 minutes.
  • “Sumiteam FP” oil: Asprgillus sp., Metal protease, manufactured by Shin Nippon Chemical Industry Co., Ltd.
  • a third protease is added to the second reaction solution by 1% by weight per protein, and others are production examples. 2 to obtain a separated walnut protein hydrolyzate 4.
  • FSP-AS-L manufactured by Nippi
  • mice were reared as follows. Purchased 8-week-old “C57BL / 6” from Nippon Charles River Co., Ltd. Rearing was carried out for 1 week at 25 ⁇ 1 ° C. under a 12 hour light-dark cycle condition (8: 00-20: 00 light period, 20: 00-8: 0 dark period). Meals were freely ingested, and “CE-2” (manufactured by Claire Japan) was fed as a solid feed.
  • Non-Patent Document 3 brain catecholamine was measured by HPLC as follows. 0.2 M perchloric acid (containing 0.1 mM EDTA ⁇ 2Na) 5 times the weight of the cerebral cortex and 100 ⁇ g of isoprotenol were added to the cerebral cortex and sufficiently crushed. After crushing, the mixture was left on ice for 30 minutes and centrifuged at 20,000 ⁇ g for 30 minutes at 4 ° C. After centrifugation, 200 ⁇ l of the supernatant was recovered, 35 ⁇ l of 0.2 M acetate buffer was added, and then filtered through a filter (0.22 ⁇ m, Merck Millipore) to remove proteins. After removing the protein, it was subjected to HPLC (HTEC-500: manufactured by Acom Co., Ltd.) to measure catecholamines.
  • HPLC HPLC
  • the molecular weight distribution of the walnut protein hydrolyzate was measured by the HPLC method using the following gel filtration column.
  • An HPLC system using a gel filtration column for peptides was assembled, a known peptide serving as a molecular weight marker was charged, and a calibration curve was obtained in relation to the molecular weight and the retention time.
  • the molecular weight markers are [ ⁇ -Asp] -Angiotensin II ⁇ -Asp-Arg-Val-Tyr-Ile-His-Pro-PHe (molecular weight 1046) as octapeptide and Angiotensin IV Val-Tyr- as hexapeptide.
  • the ratio (%) of the peptide fraction with a molecular weight of 500 or less to the total amount of peptide and free amino acid in the hydrolyzate is determined by the ratio of the area with a molecular weight of 500 or less (time range) to the total absorbance chart area. Determined (column used: Superdex Peptide 7.5 / 300GL (manufactured by GE Healthcare Japan). Solvent: 1 wt% SDS / 10 mM phosphate buffer, pH 8.0, column temperature 25 ° C, flow rate 0.25 ml / min, Detection wavelength: 220 nm).
  • the free amino acid content in the walnut protein hydrolyzate was measured by amino acid analysis.
  • the hydrolyzate (4 mg / ml) was added to an equal amount of 3% by weight sulfosalicylic acid and shaken at room temperature for 15 minutes. Centrifugation was carried out at 10,000 rpm for 10 minutes, and the resulting supernatant was filtered through a 0.45 ⁇ m filter, and free amino acids were measured with an amino acid analyzer (JLC500V manufactured by JEOL Ltd.).
  • the free amino acid content in the protein was calculated as a ratio to the protein content obtained by the Kjeldahl method.
  • the value obtained by subtracting the “free amino acid content” from the “ratio of the peptide fraction having a molecular weight of 500 or less” obtained above and further dividing by the total protein mass is the “di-tripeptide content in the hydrolyzate”.
  • the term “di-tripeptide content” means the content of “dipeptide and / or tripeptide” described in the claims of the present invention.
  • Example 1 Comparative Examples 1 to 3
  • Example 1 Comparative Examples 1 to 3
  • Noradrenaline and dopamine are widely known as major neurotransmitters in the brain, and are strongly involved in human important factors such as cognition, memory and emotion.
  • the concentration of 3-methoxy-4-hydroxyphenylglycol, its metabolite also increases, so the increased noradrenaline is efficiently used and metabolized in the brain.
  • Table 1 since the walnut protein hydrolyzate 4 used in the examples contains almost no lipid, the brain function of the walnut protein hydrolyzate 4 in Example 1 by oral ingestion. The improvement effect is considered to be due to peptides mainly contained in the walnut protein hydrolyzate 4. From the above, it was strongly suggested that the intake of walnut protein hydrolyzate 4 has a brain function improving effect specifically.
  • Example 2 Arg-Tyr, Tyr-Asn, Phe-Tyr, and Tyr-Phe were orally administered to mice, and the cerebral cortex was removed in the same manner as in Example 1 to obtain 3-methoxy-4-hydroxyphenyl in the brain. Glycol (MHPG) was measured. In addition, Arg-Tyr, Tyr-Asn, Phe-Tyr, and Tyr-Phe used what was commissioned-synthesized by Genscript Japan. The measurement results are shown in FIG.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Psychiatry (AREA)
  • Botany (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Anesthesiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)

Abstract

La présente invention concerne un matériau alimentaire qui a une fonction d'amélioration de la fonction cérébrale, qui a une stabilité au stockage élevée, et qui peut être ingéré à faible coût. On a découvert qu'un hydrolysat de protéine de noix qui contient un acide aminé spécifique et qui contient un di-tripeptide en une quantité supérieure ou égale à une certaine valeur présente un effet supérieur d'amélioration de la fonction cérébrale.
PCT/JP2017/027233 2016-07-28 2017-07-27 Composition alimentaire pour améliorer la fonction cérébrale Ceased WO2018021471A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2018506349A JPWO2018021471A1 (ja) 2016-07-28 2017-07-27 脳機能改善するための食品組成物
CN201780046792.8A CN109561728A (zh) 2016-07-28 2017-07-27 用于改善脑功能的食品组合物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016148830 2016-07-28
JP2016-148830 2016-07-28

Publications (1)

Publication Number Publication Date
WO2018021471A1 true WO2018021471A1 (fr) 2018-02-01

Family

ID=61016958

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2017/027233 Ceased WO2018021471A1 (fr) 2016-07-28 2017-07-27 Composition alimentaire pour améliorer la fonction cérébrale

Country Status (3)

Country Link
JP (1) JPWO2018021471A1 (fr)
CN (1) CN109561728A (fr)
WO (1) WO2018021471A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109022525A (zh) * 2018-08-14 2018-12-18 吉林农业大学 一种改善记忆功能的核桃活性肽及其制备方法
CN110710592A (zh) * 2019-11-16 2020-01-21 四川农业大学 一种提高核桃饼粕蛋白的抗氧化活性方法
CN113845566A (zh) * 2021-11-08 2021-12-28 西北大学 一种用于预防阿尔兹海默症的核桃多肽及其应用
CN115109818A (zh) * 2022-05-31 2022-09-27 云南中医药大学 一种可透过血脑屏障核桃肽及在制备益智类产品中的应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020248947A1 (fr) * 2019-06-10 2020-12-17 杏辉天力杭州药业有限公司 Poudre d'oligopeptides de noix, son procédé de fabrication et son utilisation
CN119192289B (zh) * 2024-11-29 2025-03-28 浙江农林大学 具有清除Aβ1-42蛋白沉积的高抗氧化活性改善学习记忆力核桃衍生肽及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006347951A (ja) * 2005-06-16 2006-12-28 Yoshihiro Futamura 神経細胞活性化作用を有するトリペプチド、それからなる食品製剤、化粧品及び抗認知症剤
CN102813206A (zh) * 2012-09-12 2012-12-12 安徽燕之坊食品有限公司 一种具有补脑益智功效的食品组合物及其制备方法
CN105936927A (zh) * 2016-05-19 2016-09-14 杏辉天力（杭州）药业有限公司 一种核桃低聚肽及其制备工艺和用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103484518B (zh) * 2013-09-11 2016-03-30 邹远东 一种核桃蛋白肽及其制备方法和其应用
JP6667194B2 (ja) * 2014-04-28 2020-03-18 不二製油株式会社 脳神経疾患の予防又は脳機能改善用食品を製造するための食品添加物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006347951A (ja) * 2005-06-16 2006-12-28 Yoshihiro Futamura 神経細胞活性化作用を有するトリペプチド、それからなる食品製剤、化粧品及び抗認知症剤
CN102813206A (zh) * 2012-09-12 2012-12-12 安徽燕之坊食品有限公司 一种具有补脑益智功效的食品组合物及其制备方法
CN105936927A (zh) * 2016-05-19 2016-09-14 杏辉天力（杭州）药业有限公司 一种核桃低聚肽及其制备工艺和用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
POULOSE, SHIBU M. ET AL.: "Functional role of walnuts and acai fruits on brain health", ACS SYMPOSIUM SERIES, vol. 1129, 2013, pages 171 - 187, XP055457314 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109022525A (zh) * 2018-08-14 2018-12-18 吉林农业大学 一种改善记忆功能的核桃活性肽及其制备方法
CN110710592A (zh) * 2019-11-16 2020-01-21 四川农业大学 一种提高核桃饼粕蛋白的抗氧化活性方法
CN113845566A (zh) * 2021-11-08 2021-12-28 西北大学 一种用于预防阿尔兹海默症的核桃多肽及其应用
CN115109818A (zh) * 2022-05-31 2022-09-27 云南中医药大学 一种可透过血脑屏障核桃肽及在制备益智类产品中的应用

Also Published As

Publication number Publication date
JPWO2018021471A1 (ja) 2018-07-26
CN109561728A (zh) 2019-04-02

Similar Documents

Publication Publication Date Title
WO2018021471A1 (fr) Composition alimentaire pour améliorer la fonction cérébrale
KR101331777B1 (ko) Ｄｐｐ-ｉｖ를 억제하는 펩타이드가 풍부한 단백질가수분해물 및 이의 용도
JP5626807B2 (ja) ペプチド結合トリプトファンとポリペプチド結合トリプトファンの混合物
CN102665749B (zh) 口服抗炎剂和口服抗炎肽
JP6524176B2 (ja) プロリルオリゴペプチダーゼ阻害剤
JP2009517464A (ja) グルカゴン様ペプチド１の活性を増強するタンパク質加水分解物の使用
WO2011152330A1 (fr) Anti-oxydant contenant un hydrolysat de protéine de soja, et son utilisation
CN101171025A (zh) 新颖的营养药物性组合物
JP7428480B2 (ja) 睡眠改善用組成物及び組成物を含む食品、医薬品、飼料
JP2016149989A (ja) 睡眠障害を予防または改善するための食品添加用組成物
CN117143949A (zh) 一种南极磷虾源高f值寡肽及其在护肝中的应用
JP6667194B2 (ja) 脳神経疾患の予防又は脳機能改善用食品を製造するための食品添加物
KR102739077B1 (ko) 수벌번데기 가수분해물을 유효성분으로 포함하는 근육질환의 예방, 개선 또는 치료용 조성물, 및 이의 제조방법
JP5130829B2 (ja) クレアチンホスホキナーゼ分泌抑制組成物
JP5115530B2 (ja) 神経新生促進剤を含有する飴、グミまたは飲料
JP7392474B2 (ja) 脳機能を改善するための食品組成物
JP2005239579A (ja) 疲労回復剤及び疲労回復用食品
WO2013073648A1 (fr) Agent fonctionnel anti-inflammatoire destiné à une application par voie orale
Jin Separation and purification of antidiabetic bioactive peptide from salmon and cod waste
JP2012116817A (ja) 蛋白質組成物の加水分解物を含有する抗酸化剤
JPWO2007139128A1 (ja) クレアチンホスホキナーゼ分泌抑制組成物
WO2017150327A1 (fr) Composition d'additif alimentaire destinée à favoriser la sécrétion cérébrale de neurotrophines
JP2025152733A (ja) 環状ペプチド、その生産方法、及びその利用
JP2018115131A (ja) 糖取り込み促進用経口組成物
KR20250106864A (ko) 단백질 가수분해물을 포함한 구강붕해정의 제조 방법 및 이 방법에 의해 제조된 구강붕해정

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2018506349

Country of ref document: JP

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17834473

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17834473

Country of ref document: EP

Kind code of ref document: A1